Becton Dickinson vs Cursor

Side-by-side comparison of AI visibility scores, market position, and capabilities

Cursor leads in AI visibility (97 vs 85)

Becton Dickinson

LeaderHealthcare Tech

Enterprise

Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.

AI VisibilityBeta
Overall Score
A85
Category Rank
#37 of 290
AI Consensus
56%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
76
Gemini
93

About

Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.

Full profile

Cursor

LeaderDeveloper Tools & Platforms

Agentic IDE

$2.3B raised at $29.3B valuation; $2B+ ARR (Q1 2026); used by 50%+ of Fortune 500. Dominant commercial AI coding tool; built on VSCode fork with native agent mode. Competing with GitHub Copilot, Windsurf, and Lovable in the vibe-coding wave.

AI VisibilityBeta
Overall Score
A97
Category Rank
#1 of 1
AI Consensus
74%
Trend
up
Per Platform
ChatGPT
89
Perplexity
99
Gemini
99

About

Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities directly in the development workflow. The company serves software developers seeking to accelerate coding productivity through AI assistance while maintaining full control and understanding of their code. Cursor delivers value through contextual code suggestions that understand entire codebases, natural language commands to modify code, inline AI chat for explaining complex code, and a familiar VS Code interface that requires minimal learning curve for existing developers.

Full profile

AI Visibility Head-to-Head

85
Overall Score
97
#37
Category Rank
#1
56
AI Consensus
74
stable
Trend
up
77
ChatGPT
89
76
Perplexity
99
93
Gemini
99
87
Claude
99
79
Grok
96

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.